Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma

Nearly all patients with BRAF-mutant melanoma will progress on BRAF inhibitor monotherapy and combination BRAF/MEK inhibitor therapy within the first year of therapy. In the vast majority of progressing melanomas, resistance occurs via the re-activation of MAPK signalling, commonly via alterations i...

Descripción completa

Detalles Bibliográficos
Autores principales: Irvine, Mal, Stewart, Ashleigh, Pedersen, Bernadette, Boyd, Suzanah, Kefford, Richard, Rizos, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148266/
https://www.ncbi.nlm.nih.gov/pubmed/30237495
http://dx.doi.org/10.1038/s41389-018-0081-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148266/
https://www.ncbi.nlm.nih.gov/pubmed/30237495
http://dx.doi.org/10.1038/s41389-018-0081-3

Ejemplares similares